DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 8% to $74.17 per share. This run-up ...

DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across ...

Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NexGel Inc (NXGL – Research Report) and Dexcom ...

EDINBURGH, Scotland, and SAN DIEGO – Tech, not medicine, is the future of care for Type 2 diabetes patients, according to a new report from Dexcom.

Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments.

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 ...

Find out in our full research report, it’s free. Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ:DXCM) develops and sells continuous glucose monitoring systems that ...

Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East With a foreword from the International Diabetes Federation Europe, and recommendations for improving access to ...